IV

CourMed Selected as First Company to Access Microsoft's $50M Capital Fund to Support Small Businesses

Retrieved on: 
Tuesday, September 7, 2021

CourMed will receive access to the capital in the form of zero interest loans from Microsoft's banking partner for the program.

Key Points: 
  • CourMed will receive access to the capital in the form of zero interest loans from Microsoft's banking partner for the program.
  • CourMed officially launched in late 2018 as a pharmaceutical delivery company, working with community pharmacies to provide a concierge healthcare delivery experience to patients in the comfort of their homes.
  • The company grew its revenue by 300 percent between 2019 and 2020, even before the pandemic accelerated growth further.
  • CourMed utilizes enterprise software to facilitate the innovative concierge delivery of healthcare products and services.

Global Syringe Market (2021 to 2026) - Featuring BD, Terumo and Nipro Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 7, 2021
Health, General Health

The rise in the market may be attributed to the rising patient population base requiring injecting drugs or withdrawal of fluids for diagnostic purposes from the body.

Key Points: 
  • The rise in the market may be attributed to the rising patient population base requiring injecting drugs or withdrawal of fluids for diagnostic purposes from the body.
  • However, growing focus on alternative drug delivery methods such as patches and oral might hamper the market during the given time frame.
  • This development is expected to have a positive impact on the global syringe market, in the coming period.
  • This is development is expected to increase the overall syringe market share, during the forecast period.

Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment

Retrieved on: 
Tuesday, September 7, 2021

Foralumab is the only fully human anti-CD3 monoclonal antibody ("mAb") in clinical development in the world.

Key Points: 
  • Foralumab is the only fully human anti-CD3 monoclonal antibody ("mAb") in clinical development in the world.
  • The Company is accelerating development of anti-Interleukin 6 receptor ("IL6R") mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.
  • Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements.
  • The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made.

Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment

Retrieved on: 
Thursday, September 2, 2021
Cancer, AS, Cytokine release syndrome, CAR, Rheumatoid arthritis, SEC, Research, IBD, Intellectual property, Achievement, NOW, Graft-versus-host disease, Genome, Therapy, Disease, Cell, Forward-looking statement, EU, Psoriasis, Investor, Â, Technology, Industry, Cluster, T1D, Infection, TRAC, IV, Insurance, THIS, Nasdaq, OF, Inflammation, Mab, Crohn's disease, NEW, Autoimmunity, Immunotherapy, Biotechnology, Cluster of differentiation, Degenerative disease, THE, Cytokine, Multiple sclerosis, Company, Private Securities Litigation Reform Act, Growth, Ownership, TLSA, GLOBE, LSE, Precision, TILS, Patient, Compliance, List, COVID-19, TCR, Inflammatory bowel disease, Vaccine, Pharmaceutical industry, Public relations, Risk management

Under the terms of the agreement, Precision gains an exclusive license to use foralumab as a lymphodepletion agent in conjunction with its allogeneic CAR T therapeutics for the treatment of cancers.

Key Points: 
  • Under the terms of the agreement, Precision gains an exclusive license to use foralumab as a lymphodepletion agent in conjunction with its allogeneic CAR T therapeutics for the treatment of cancers.
  • While CAR T therapies have been clinically successful, relapse rates remain high, which continues to limit broad utility.
  • Precision is advancing a pipeline of cell-phenotype optimized allogeneic CAR T therapies, leveraging fully scaled, proprietary manufacturing processes.
  • The Company's allogeneic CAR T platform is designed to maximize the number of patients who can potentially benefit from CAR T therapy.

Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment

Retrieved on: 
Thursday, September 2, 2021
Research, Genetics, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Oncology, Cancer, Cytokine release syndrome, CAR, Rheumatoid arthritis, SEC, Research, IBD, Intellectual property, Achievement, Graft-versus-host disease, Genome, Therapy, Disease, Cell, Forward-looking statement, Psoriasis, Investor, Â, UK, Technology, Industry, Cluster, T1D, Infection, TRAC, IV, Insurance, Nasdaq, Inflammation, Mab, Crohn's disease, Autoimmunity, Immunotherapy, Biotechnology, Cluster of differentiation, Degenerative disease, Cytokine, Multiple sclerosis, Company, Private Securities Litigation Reform Act, Growth, Ownership, TLSA, LSE, Precision, Multimedia, TILS, Patient, Compliance, List, COVID-19, TCR, Inflammatory bowel disease, Vaccine, Pharmaceutical industry, Risk management, Precision’s Allogeneic CAR T Platform, Foralumab, Precision BioSciences, Inc., Tiziana Life Sciences plc, PRECISION’S ALLOGENEIC CAR T PLATFORM, FORALUMAB, PRECISION BIOSCIENCES, INC., TIZIANA LIFE SCIENCES PLC

Precisions manufacturing process, which uses ARCUS to knock out the TRAC gene and implements a CD3-depletion step, produces allogeneic CAR T candidates that are >99.9% CD3-negative.

Key Points: 
  • Precisions manufacturing process, which uses ARCUS to knock out the TRAC gene and implements a CD3-depletion step, produces allogeneic CAR T candidates that are >99.9% CD3-negative.
  • Under the terms of the agreement, Precision gains an exclusive license to use foralumab as a lymphodepletion agent in conjunction with its allogeneic CAR T therapeutics for the treatment of cancers.
  • Precision is advancing a pipeline of cell-phenotype optimized allogeneic CAR T therapies, leveraging fully scaled, proprietary manufacturing processes.
  • The Company's allogeneic CAR T platform is designed to maximize the number of patients who can potentially benefit from CAR T therapy.

Twelve and LanzaTech Partner to Produce the World’s First Polypropylene From CO2

Retrieved on: 
Wednesday, September 1, 2021
Biotechnology, Health, Environment, Medical Devices, Syringe, Engineering, Plant, Climate, IV, CO2, Machine learning, Synthetic biology, Chemistry, Biology, Â, Barclays, Partnership, Solution, Ethanol, Aviation biofuel, Textile, Water, Atmosphere, Climate change, Artificial intelligence, Technology, Fossil fuel, Renewable energy

Twelves carbon transformation technology converts CO2 into materials that are traditionally made from fossil fuels.

Key Points: 
  • Twelves carbon transformation technology converts CO2 into materials that are traditionally made from fossil fuels.
  • LanzaTechs carbon recycling Pollution To Products technology uses nature-based solutions to produce ethanol and other materials from waste carbon sources.
  • Polypropylene is a key material for essential medical supplies and for many products we rely on in our daily lives.
  • We now have a way to produce this critical material from CO2 and water instead of from fossil fuels, with no tradeoffs in quality, efficacy or performance.

IV Vitamin Therapy Franchise is Expanding to The Motor City

Retrieved on: 
Tuesday, August 31, 2021
Health care, Ageing, Vitamin, Cancer, IV, Conditional sentence, Health, Absorption, Mental health, Nutrient, Multimedia, Foot, Patient, CEO, C (musical note), THE, Human, Brain, COVID-19, Dietary supplement, Pharmaceutical industry

According to Chief Development Officer Ben Crosbie, THE DRIPBaR is expected to open as many as 40 locations this year.

Key Points: 
  • According to Chief Development Officer Ben Crosbie, THE DRIPBaR is expected to open as many as 40 locations this year.
  • With people becoming more health minded and proactive, they are making THE DRIPBaR a part of their regular wellness routine," notes Crosbie.
  • Intravenous vitamin therapy, which is also known as IV therapy, is the administering of nutrients and hydration directly into the bloodstream for immediate absorption and use by the body.
  • Including a franchise fee of $55,000, the initial investment to open a 1,000 - 1,500 square foot location is around $131,700 to $278,300.

Family-owned HealthIV Makes Public Launch with Respected Pharmacist at the Helm

Retrieved on: 
Tuesday, August 31, 2021
Face, Human, Chief medical informatics officer, Family, IV, Leadership, Naturopathy, Pharmacy, Digital technology, Pharmacist, Injury, Hospital, Medical director, Patient, Biochemistry, CEO, Digital, Doctor of Pharmacy, Weight loss, Health, Medicine, Healthcare

With Ahmed at the helm, HealthIV is poised to make significant impacts on the home healthcare space, with a particular focus on creating full digital interoperability between patients, doctors, pharmacists, and home healthcare workers.

Key Points: 
  • With Ahmed at the helm, HealthIV is poised to make significant impacts on the home healthcare space, with a particular focus on creating full digital interoperability between patients, doctors, pharmacists, and home healthcare workers.
  • She will also serve as the primary staff practitioner, taking a keen interest in the wellbeing of patients using HealthIV's home healthcare and IV delivery services.
  • Ahmed brings a wealth of experience in medicine and pharmaceuticals to her leadership role at HealthIV.
  • Soon, the company will launch a mobile app connecting patients, providers, and pharmacies in unprecedented ways.

CSG Government Solutions Selected by the Georgia Department of Community Health to Provide IV&V Services for the Medicaid Enterprise System Transformation Project

Retrieved on: 
Tuesday, August 31, 2021
Independent verification systems, Government, Health care, Human services, Community, Georgia Department of Community Supervision, IV, Knowledge, DCH, CSG, Office of Inspector General, U.S. Department of Health and Human Services, Goal, IV&V, U.S. Department of Labor, Office of Inspector General, Medicaid, Risk management, Management

CHICAGO, Aug. 31, 2021 /PRNewswire-PRWeb/ -- CSG Government Solutions, a national leader in government program modernization, today announced that it has been selected by the Georgia Department of Community Health to provide Independent Verification and Validation (IV&V) services for its Medicaid Enterprise System Transformation project.

Key Points: 
  • CHICAGO, Aug. 31, 2021 /PRNewswire-PRWeb/ -- CSG Government Solutions, a national leader in government program modernization, today announced that it has been selected by the Georgia Department of Community Health to provide Independent Verification and Validation (IV&V) services for its Medicaid Enterprise System Transformation project.
  • Georgia is using a modular approach to transform its legacy Medicaid system.
  • CSG Government Solutions deploys highly experienced teams and innovative methods, knowledge, and tools to help governments modernize complex program enterprises.
  • CSG clients include 46 state and territory governments, the U.S. Department of Health and Human Services, the U.S. Department of Labor, and large municipal governments.

Direct Relief Commits $1 Million in Funding, Offers Medical Inventory for Hurricane Ida Recovery

Retrieved on: 
Tuesday, August 31, 2021
Politics, Tropical cyclone, Religion, Lists of disasters, Community, Trauma, IV, Diabetes, Mississippi Federation of Women's Clubs, Hurricane Ida, Health, Multimedia, Community health center, Hypertension, Common Ground Health Clinic, OTC, Poverty, Direct Relief, Patient, CEO, Health information management, Insulin, COVID-19, Emergency, Medicine, Pharmaceutical industry, Hospital

On Sunday morning, Direct Relief sent an alert to 214 partners in Louisiana and Mississippi Federally Qualified Health Centers (FQHCs) and free clinics in both states informing them that they are pre-approved to order emergency-specific medical resources free-of-charge from Direct Relief's inventory.

Key Points: 
  • On Sunday morning, Direct Relief sent an alert to 214 partners in Louisiana and Mississippi Federally Qualified Health Centers (FQHCs) and free clinics in both states informing them that they are pre-approved to order emergency-specific medical resources free-of-charge from Direct Relief's inventory.
  • Available items include antibiotics, chronic disease medications, insulin, IV solutions, OTC medical products, and much more.
  • On Monday, Direct Relief extended the offer to 85 partners in Tennessee and 73 contacts in eastern Texas.
  • Prior to the storm, Direct Relief had prepositioned 17 Hurricane Preparedness Packs with partner facilities in areas impacted by Ida.